CheckpointRecent Data Breaches and Security Report

https://checkpointtx.com  ᛫ 
Last updated October 26, 2018

Company Details

Company Overview

Checkpoint Therapeutics, Inc. (�Checkpoint�) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (�NSCLC�). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-na�ve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

Valuation

Employees

CEO

Location

Recent Data Breaches

Stay informed about the most recent data breaches affecting companies like Checkpoint

subscribe to data breach notifications

Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's CSTAR Score ranges from 0 to 950. The higher the score, the more effective a company is in implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Checkpoint

Get full security report ›

See UpGuard In Action

Book a call with one of our specialists and we'll arrange a time for a demo.